Coronavirus (COVID-19) Current Therapy Market Opportunities and Strategies to 2034: Digital Solutions Transforming Accessibility, Advancements in Antiviral Drug Development, Strategic Investments - ResearchAndMarkets.com

The "Coronavirus (COVID-19) Current Therapy Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.

This report describes and explains the coronavirus (COVID-19) current therapy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global coronavirus (COVID-19) current therapy market reached a value of nearly $9.36 billion in 2024. The market is expected to grow from $9.36 billion in 2024 to $541.44 million in 2029 at a rate of -43.46%. The market is then expected to grow at a CAGR of -100% from 2029.

Growth in the historic period resulted from the new COVID-19 strains and impact of COVID-19 pandemic, increasing adoption of telemedicine, expanding clinical trials and rising vaccination programs. Factors that negatively affected growth in the historic period were regulatory hurdles. Going forward, the rising prevalence of chronic diseases, increasing aging population, increase in healthcare expenditure and favorable government initiatives will drive the growth. Factor that could hinder the growth of the coronavirus (COVID-19) current therapy market in the future include high cost of therapies and decline in demand for COVID-19 therapeutics.

The global coronavirus (COVID-19) current therapy market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 40.4% of the total market in 2023. Gilead Sciences, Inc. was the largest competitor with a 18.61% share of the market, followed by Merck & Co. with 12.17%, Regeneron Pharmaceuticals, Inc. with 5.27%, F. Hoffmann-La Roche AG. with 0.96%, Ipca Laboratories Limited. with 0.66%, Zydus Group. with 0.65%, Sun Pharmaceutical Industries Limited with 0.61%, AbbVie Inc. with 0.52%, Pfizer Inc. with 0.49% and Glenmark Pharmaceuticals Limited with 0.46%.

The coronavirus (COVID-19) current therapy market is segmented by drug type into antivirals, Mabs, corticosteroid, supplements, antimalarial, interferons and interleukin inhibitors, other anti-infections and others. The antiviral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug type, accounting for 29.54% or $2.76 billion of the total in 2024. Going forward, the mabs segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by drug type, at a CAGR of -40.94% during 2024-2029.

The coronavirus (COVID-19) current therapy market is segmented by route of administration into oral and intravenous. The oral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by route of administration, accounting for 64.28% or $6.02 billion of the total in 2024. Going forward, the intravenous segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by route of administration, at a CAGR of -40.16% during 2024-2029.

The COVID-19 current therapy market is segmented by end-user into hospitals, clinics, home care and other end-users. The hospitals market was the largest segment of the COVID-19 current therapy market segmented by end-user, accounting for 57.49% or $5.38 billion of the total in 2024. Going forward, the home care segment is expected to be the fastest growing segment in the COVID-19 current therapy market segmented by end-user, at a CAGR of -42.36% during 2024-2029.

North America was the largest region in the coronavirus (COVID-19) current therapy market, accounting for 54.44% or $5.09 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the coronavirus (COVID-19) current therapy market will be North America and Western Europe where growth will be at CAGRs of -40.16% and -42.83% respectively. These will be followed by Asia-Pacific and Eastern Europe where the markets are expected to grow at CAGRs of -50.58% and -53.28% respectively.

The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by drug type will arise in the supplements segment, which will gain $-80.63 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy market segmented by route of administration will arise in the intravenous segment, which will gain $-3,089.5 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by end-user will arise in the other end-users segment, which will gain $-827.84 million of global annual sales by 2029. The coronavirus (COVID-19) current therapy market size will gain the most in Indonesia at $-32.3 million.

Market-trend-based strategies for the COVID-19 current therapy market include focus on strategic investments to accelerate the development of effective therapies and expand clinical research, focus on developing antiviral drugs and focus on developing innovative digital platforms. Player-adopted strategies in the coronavirus (COVID-19) current therapy market include focus on expanding its business capabilities through new clinical trials and focuses on enhancing its operational capabilities through strategic partnerships and drug approvals.

To take advantage of the opportunities, the analyst recommends the COVID-19 current therapy companies to focus on strategic investments and R&D for growth, focus on developing targeted antiviral therapies, focus on innovating digital platforms for enhanced patient care, focus on the "others" anti-infections segment, focus on the oral segment, expand in emerging markets, focus on expanding distribution channels to enhance accessibility, focus on strategic pricing to maximize market penetration, focus on building trust and credibility for COVID-19 therapy companies, focus on strategic partnerships with healthcare providers and insurers to boost product adoption and focus on the home care market.

Major Market Trends

• Strategic Investments Driving COVID-19 Therapy Market Growth
• Advancements in Antiviral Drug Development for COVID-19 Treatment
• Digital Solutions Transforming Healthcare Accessibility

Key Mergers and Acquisitions

• GSK Acquires CureVac
• FSII-Pardes Biosciences Merger Aims to Enhance COVID-19 Antiviral Therapy Capabilities

Companies Featured

• Gilead Sciences, Inc.
• Merck & Co
• Regeneron Pharmaceuticals, Inc
• F. Hoffmann-La Roche AG
• Ipca Laboratories Limited
• Zydus Group
• Sun Pharmaceutical Industries Limited
• AbbVie Inc
• Pfizer Inc
• Glenmark Pharmaceuticals Limited
• Lupin Limited
• Cipla Limited
• Bajaj Healthcare
• CSPC Pharmaceutical Group
• 111 Inc
• Brii Bio
• Pharmaceutical Commercial Group
• Sinopharm Holding Co
• Advaccine Biopharmaceutical
• Shionogi & Co., Ltd
• Takeda Pharmaceutical Company
• Mylab Discovery Solutions
• Kalbe Farma
• He Qi Group Foundation
• Beijing Jinwofu Bioengineering Technology
• Zhejiang Orient Gene Biotech Co. Ltd
• Transasia Bio Medicals
• Vanguard Diagnostics
• HLL Lifecare Limited
• Voxtur Bio Ltd
• LAB-CARE Diagnostics
• CPC Diagnostics
• Seegene
• SD Biosensor
• Getein Biotech
• Hangzhou Biotest Biotech
• AmonMed Biotechnology
• Beijing Tigsun Diagnostics
• Hunan Lituo Biotechnology
• Vivacheck Lab
• Fujirebio
• Sysmex Corporation
• Atomo Diagnostics
• Motologic
• Siemens Healthcare Pte Ltd
• Senova
• LetsGetChecked
• Omega Diagnostics
• Abingdon Health
• Babylon
• Novacyt Group
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Novartis AG
• Sanofi
• Amarin Corporation
• Roivant Sciences
• ViroBlock
• Zentiva
• AbbVie Inc.
• Pfizer Inc.
• Adagio Therapeutics
• INOVIO Pharmaceuticals
• ImmunoScience
• Abbott Laboratories
• Mylan
• Eli Lilly and Company
• Sorrento Therapeutics, Inc.
• Ridgeback Biotherapeutics
• Veru Inc
• NRx Pharmaceuticals Inc
• Thermo Fisher Scientific
• CytoDyn
• Atea Pharmaceuticals Inc
• Alexion Pharmaceuticals
• Johnson & Johnson Ltd
• Genentech Inc.
• Moderna
• Canary Health Technologies
• BioMedomics
• CTK Biotech
• Teva Pharmaceutical Industries Ltd
• Abdi Ibrahim Pharmaceuticals
• Julphar
• G42 Healthcare
• SaudiVax
• CapeBio
• Astel Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/tnn1ni

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508984024/en/